Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Lactoferrin  COVID-19 treatment studies for Lactoferrin  C19 studies: Lactoferrin  Lactoferrin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Time to viral- 47% Improvement Relative Risk Time to viral- (b) 56% c19early.org/lf Campione et al. Lactoferrin for COVID-19 EARLY Is early treatment with lactoferrin beneficial for COVID-19? Prospective study of 64 patients in Italy Faster viral clearance with lactoferrin (p=0.0001) Campione et al., Int. J. Environmental Research .., doi:10.3390/ijerph182010985 Favors lactoferrin Favors control
Lactoferrin as Antiviral Treatment in COVID-19 Management: Preliminary Evidence
Campione et al., International Journal of Environmental Research and Public Health, doi:10.3390/ijerph182010985
Campione et al., Lactoferrin as Antiviral Treatment in COVID-19 Management: Preliminary Evidence, International Journal of Environmental Research and Public Health, doi:10.3390/ijerph182010985
Oct 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small prospective study in Italy with 32 lactoferrin patients, 32 SOC, and 28 patients with no treatment, showing significantly faster viral clearance and improved recovery with treatment. Oral and intranasal lactoferrin.
time to viral-, 47.5% lower, relative time 0.53, p < 0.001, treatment 32, control 32, vs. SOC.
time to viral-, 56.3% lower, relative time 0.44, p < 0.001, treatment 32, control 28, vs. untreated.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Campione et al., 19 Oct 2021, prospective, Italy, peer-reviewed, 32 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperLactoferrinAll
Abstract: International Journal of Environmental Research and Public Health Article Lactoferrin as Antiviral Treatment in COVID-19 Management: Preliminary Evidence Elena Campione 1, *, Caterina Lanna 1 , Terenzio Cosio 1 , Luigi Rosa 2 , Maria Pia Conte 2 , Federico Iacovelli 3 , Alice Romeo 3 , Mattia Falconi 3 , Claudia Del Vecchio 4 , Elisa Franchin 4 , Maria Stella Lia 5 , Marilena Minieri 5 , Carlo Chiaramonte 6 , Marco Ciotti 7 , Marzia Nuccetelli 8 , Alessandro Terrinoni 5 , Ilaria Iannuzzi 9 , Luca Coppeta 9 , Andrea Magrini 9 , Sergio Bernardini 8 , Stefano Sabatini 10 , Felice Rosapepe 11 , Pier Luigi Bartoletti 12 , Nicola Moricca 10 , Andrea Di Lorenzo 13 , Massimo Andreoni 13 , Loredana Sarmati 13 , Alessandro Miani 14 , Prisco Piscitelli 15 , Ettore Squillaci 16 , Piera Valenti 2,† and Luca Bianchi 1,† 1 2 3 4 5   Citation: Campione, E.; Lanna, C.; 6 7 8 Cosio, T.; Rosa, L.; Conte, M.P.; Iacovelli, F.; Romeo, A.; Falconi, M.; Del Vecchio, C.; Franchin, E.; et al. Lactoferrin as Antiviral Treatment in 9 10 11 COVID-19 Management: Preliminary 12 Evidence. Int. J. Environ. Res. Public 13 Health 2021, 18, 10985. https:// doi.org/10.3390/ijerph182010985 14 Academic Editor: Paul B. Tchounwou 15 Received: 4 August 2021 Accepted: 13 October 2021 Published: 19 October 2021 16 * † Dermatology Unit, Department of Systems Medicine, Tor Vergata University Hospital, 00133 Rome, Italy; caterinalanna.cl@gmail.com (C.L.); terenziocosio@gmail.com (T.C.); luca.bianchi@uniroma2.it (L.B.) Department of Public Health and Infectious Diseases, University of Rome “La Sapienza”, 00185 Rome, Italy; luigi.rosa@uniroma1.it (L.R.); mariapia.conte@uniroma1.it (M.P.C.); piera.valenti@uniroma1.it (P.V.) Structural Bioinformatics Group, Department of Biology, University of Rome “Tor Vergata”, 00133 Rome, Italy; federico.iacovelli@uniroma2.it (F.I.); alice.romeo@uniroma2.it (A.R.); falconi@uniroma2.it (M.F.) Department of Molecular Medicine, University of Padova, 35122 Padova, Italy; claudia.delvecchio@unipd.it (C.D.V.); elisa.franchin@unipd.it (E.F.) Department of Experimental Medicine, Tor Vergata University Hospital, 00133 Rome, Italy; lia.mariastella@gmail.com (M.S.L.); minieri@med.uniroma2.it (M.M.); alessandro.terrinoni@uniroma2.it (A.T.) Department of Statistics, University of Rome Tor Vergata, 00133 Rome, Italy; chiaramonte.carlo43@gmail.com Virology Unit, Tor Vergata University Hospital, 00133 Rome, Italy; marco.ciotti@ptvonline.it Laboratory Medicine, Department of Experimental Medicine and Surgery, Tor Vergata University Hospital, 00133 Rome, Italy; marzianuccetelli@yahoo.com (M.N.); bernardini@med.uniroma2.it (S.B.) Occupational Medicine Department, University of Rome “Tor Vergata”, 00133 Rome, Italy; ilariaiannuzzi@gmail.com (I.I.); luca.coppeta@gmail.com (L.C.); andrea.magrini@uniroma2.it (A.M.) Villa dei Pini Hospital, 00042 Anzio, Italy; stefanosabatini@gmail.com (S.S.); nicolamoricca@gmail.com (N.M.) Pineta Grande Hospital, 81030 Caserta, Italy; frosapepe@gmail.com Fimmg Provincial, 00144 Rome, Italy; pl.bartoletti@gmail.com Infectious Disease Unit, Tor Vergata University Hospital, 00133 Rome, Italy; andrea.dilorenzo@alumni.uniroma2.eu (A.D.L.); andreoni@uniroma2.it (M.A.); sarmati@med.uniroma2.it (L.S.) Department of Environmental Sciences and Policy, University of Milan, 20133 Milan, Italy; alessandro.miani@unimi.it UNESCO Chair on Health Education and Sustainable Development, University of Naples Federico..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit